of note , however , galnt2 drug1 -lrb- previously associate with high-density lipoprotein cholesterol level in ea -rrb- have multiple potentially novel phewas association , with hypertension related phenotype in aa and with serum calcium level and drug2 phenotype in ea . 
the majority of the potentially novel result be for single phewas phenotype-class , for example , for cdkn2a/b drug1 -lrb- previously associate with type 2 drug2 in ea -rrb- a phewas association be identify for hemoglobin level in aa . 
however , the effect of drug1 : c > g in ink4 locus in familial drug2 patient and on lipid profile of the patient have not be study in Pakistan . 
a epistatic interaction between drug1 and drug2 -lrb- or 1.56 , p = 1.19 * 10 -lrb- -2 -rrb- -rrb- be find especially in presence of drug3 disease -lrb- or = 2.15 , p = 3.12 * 10 -lrb- -4 -rrb- -rrb- . 
in a longitudinal study with 11 year of follow-up on survival in the oldest-old Danes , only one snp , drug1 -lrb- il6 -rrb- , be borderline significantly associate with drug2 from age 92 -lrb- p-corrected = 0.064 -rrb- . 
haplotype of drug1 and drug2 or drug3 and drug4 reveal a association with drug5 cancer which be significantly stronger in the homozygous carrier . 
the nonsynonymous oprm1 drug1 might be a risk factor for drug2 to opioid or heroin in a asian population . 
no association be find between drug2 phenotype -lrb- incidence , intensity , and duration -rrb- and different drug1 genotype . 
result reveal a association between drug1 and cocaine and heroin drug2 in european american -lrb- p = 0.02 ; 95 % C.I. 0.47 -lsb- 0.24-0 .92 -rsb- -rrb- 
the 118g allele confer 5.3-fold increase odds of drug2 / drug3 -lrb- p < 0.05 -rrb- , while the drug1 variant allele be not associate with drug4 / drug5 
in this meta analysis , we assess 10 case-control study include 7,067 case and 9,374 control of the association between cyp1b1 snp of leu432val -lrb- drug1 , 432c > g -rrb- , asn453ser -lrb- drug2 , 453a > g -rrb- , ala119ser -lrb- drug3 , 119g > t -rrb- , arg48gly -lrb- drug4 , 48c > g -rrb- and the risk of drug5 . 
result : in we human study , the a118g singlenucleotide polymorphism drug1 be associate with drug2 virus disease severity -lrb- p = 0.015 -rrb- . 
compare to control , drug3 patient -lrb- with and without drug4 -rrb- show significantly increase frequency of the dbh -lrb- drug1 : or 1.73 ; ci 1.15-2 .59 ; p = 0.008 -rrb- and the oprm1 risk genotype -lrb- drug2 : or 1.71 ; ci 1.17-2 .50 ; p = 0.006 -rrb- . 
in the present study we investigate whether the drug1 snp could predict clinical outcome regard progression of drug2 and disability in patient with low drug3 and drug4 after drug5 herniation . 
earlier study have show that the single nucleotide polymorphism drug1 in the opioid receptor mu 1 -lrb- oprm1 -rrb- gene may affect drug2 . 
individual be genotype for pcsk9 r46l -lrb- drug1 -rrb- , abcg8 d19h -lrb- drug2 -rrb- , and APOE r112c -lrb- drug3 -rrb- and r158c drug4 polymorphism , all of which be associate with drug5 
male child of alcoholic be less likely to be carrier of the g allele in single nucleotide polymorphism a118g -lrb- drug1 -rrb- , and those who be homozygous for the a allele be more likely to affiliate with alcohol use promote peer who increase the risk for drug2 symptom at all age . 
the COMT drug1 gene polymorphism have be investigate as a susceptibility factor for drug2 . 
no statistically significant result be find in meta-analysis but one study report that the drug1 allele be associate with drug2 . 
the COMT drug1 polymorphism be also find to modulate drug2 in normal people and drug3 . 
whites with allele g of the functional polymorphism 118a > g -lrb- reference sequence drug1 -rrb- show a smaller decrease in drug2 ; those bear minor allele ivs1 + 1050a , ivs1 + 14123a , and ivs2 + 31a show a larger decrease in drug3 over interval x -lrb- 0.01 < p < .05 -rrb- 
conflicting result be report on the role of the mu-opioid receptor -lrb- oprm1 -rrb- polymorphism a118g -lrb- asn40asp , drug1 -rrb- in the development of drug2 . 
drug3 be more sensitive to experimental pain than healthy volunteer and , in particular , drug4 individual with the met/met genotype -lrb- drug1 snp -rrb- or the hps-aps haplotype show higher drug5 stimulus than patient carry the lps haplotype or val allele -lrb- drug2 np -rrb- . 
accord with previous research , we finding reveal that haplotype of the COMT geneand genotype of the drug1 polymorphism play a key role on pain sensitivity in drug2 . 
we assess 10 case-control study include 7,067 case and 9,374 control of the association between cyp1b1 snp of leu432val drug1 asn453ser drug2 , ala119ser drug3 , drug4 nd the risk of drug5 . 
we result suggest that there be no direct effect of drug1 genotype on the risk for drug2 among active heroin user . 
this study aim to investigate association between subjective response to drug2 and genetic polymorphism and haplotype in the u-opioid receptor include the exonic variant drug1 -lrb- asp40asn -rrb- . 
the study be focus on the relationship between the functional a118g polymorphism of the oprm1 gene -lrb- drug1 -rrb- and drug2 in group of 130 male patient and 452 male control . 
the result of the present study reveal that the drug1 gene polymorphism be associate with a better glucose tolerance and improve be , both of which suggest a potential protective effect of this variant on drug2 risk . . 
moreover , we find that the drug1 allele be a dose-response protective factor for drug2 and the epsilon3 allele exert a weaker dose-response protective effect for risk of ad compare with epsilon2 . 
drug1 be not significantly associate with drug2 in we sample . 
objective : previous study have investigate the role of drug1 -lrb- ctla-4 -rrb- and drug2 factor-alpha -lrb- tnf-a -rrb- in carcinogenesis of osteosarcoma , but they result be inconsistent . 
pool result show that drug1 polymorphism of ctla-4 be associate with drug2 -lrb- 
no significant association be find between drug1 polymorphism of ctla-4 or drug2 polymorphism of tnf-a and drug3 risk . 
the COMT drug1 genotype be associate with higher drug2 on the bis-11 second-order factor non-planning . 
in the total population , inheritance of the il1r2 drug1 aa , drug2 aa , tnf drug3 ga + aa , and tnf rs673 ga genotypesmodestly increase drug4 risk by 1.45 to 11.7-fold relative to the referent genotype . 
among U.S. man , age-adjusted dominant , recessive and additive genetic model for the il1r2 drug1 locus be link to a increase in drug2 susceptibility . 
as for drug1 polymorphism , the heterogeneous genotype show a decrease risk for drug2 compare with the common homogenous genotype in a fixed-effect model in asian population -lrb- met/val vs. 
in order to study specific feature of remit multiple sclerosis patient with different genotype of polymorphic locus rs1800629 gene tnfa , drug1 gene cd40 , drug2 gene kif1b , drug3 il-18 gene , conduct clinical and electrophysiological examination of 149 patient with drug4 . 
we have determine 4 frequent nonsynonymous gene polymorphism of cyp1b1 in the human drug5 cell line panel of the National Cancer Institut e -lrb- nci -rrb- and the japanese Foundation for Cancer Research -lrb- jfcr -rrb- : drug1 -lrb- r48g -rrb- , drug2 -lrb- a119s -rrb- , drug3 -lrb- l432v -rrb- , and drug4 -lrb- n453s -rrb- . 
background : evidence have suggest that tumour necrosis factor -lrb- tnf -rrb- - a may be involve in the aetiology of drug3 , but the underlying association of the tnf-a polymorphism -238 g/a -lrb- drug1 -rrb- and -308 g/a -lrb- drug2 -rrb- with the risk of drug4 be still unconfirmed . 
evidence have suggest that tumour necrosis factor -lrb- tnf -rrb- - a may be involve in the aetiology of psoriasis , but the underlying association of the tnf-a polymorphism -238 g/a drug1 and -308 g/a drug2 with the risk of drug3 be still <modmar> unconfirmed <modmar> 
conclusion : we have confirm association between drug3 and drug1 and drug2 . 
objective : we have conduct the first study of the association of interleukin -lrb- il -rrb- -10 , tumor necrosis factor alpha -lrb- tnf-a -rrb- , and drug1 region single nucleotide polymorphism -lrb- snp -rrb- with drug2 in western Algeria . 
we result show a potential influence of the drug1 deletion on the risk of drug2 disease among patient with drug3 . 
there be no association of drug1 with drug2 in the combined sample -lrb- n = 4071 , p = 0.110 , odds ratio = 1.08 -rrb- . 
we result do not support the association of drug1 with drug2 in the Han Chinese population . 
background : genotype of tumor necrosis factor alpha -lrb- tnf-a -rrb- and its surface receptor , drug1 and drug2 , have be examine in term of the progression , metastasis , clinical efficacy , and prognosis of various cancer ; however , little be know about they effect on clinical outcome in patient with drug3 -lrb- escc -rrb- . 
drug1 genotype be predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in japanese patient with esophageal squamous cell drug2 . 
overall,tnf-a drug1 polymorphism be significantly associate with the increase risk of drug2 under four genetic comparison model 
remarkably , drug1 be a protective factor to drug2 when compare with BPH -lrb- or = 0.550 ; 95 % ci = 0.311-0 .975 -rrb- , although the statistically significant difference be lose after correction for multiple comparison . 
no significant association of drug1 variant be observe with drug2 , drug3 or drug4 clinicopathologic status . 
we have determine 4 frequent nonsynonymous gene polymorphism of cyp1b1 in the human tumor cell line panel of the National CancerInstitute -lrb- NCI -rrb- and the japanese Foundation for drug5 Research -lrb- jfcr -rrb- : drug1 -lrb- r48g -rrb- , drug2 -lrb- a119s -rrb- , drug3 -lrb- l432v -rrb- , and drug4 -lrb- n453s -rrb- 
seven polymorphic variant in gene drug1 , drug2 , drug3 , drug4 , drug5 , drug6 and drug7 be associate with drug8 . 
Noteworthy , the considerable number of patient carry drug1 and drug2 allele underlie the importance of consider pharmacogenetic testing before start drug therapy protocol to prevent toxicity and/or lack of effectiveness in drug3 or drug4 virus infection . 
logistic regression analysis identify two variant associate with drug3 , the 32-bp deletion within drug1 and the drug2 within the mthfr gene . 
univariate analysis detect one significant single-nucleotide polymorphism -lrb- p = 0.03 -rrb- , drug1 , within the methylenetetrahydrofolate reductase -lrb- mthfr -rrb- gene associate with drug2 . 
logistic regression analysis identify two variant associate with drug3 , the 32-bp deletion within drug1 and the p. 222a/v variant -lrb- drug2 -rrb- within the mthfr gene . 
we explore the influence of interaction between polymorphism act upon postsynaptic receptor -lrb- drd2 taqa1 drug1 and drd4 7r -rrb- and dopamine regulator -lrb- comt drug2 and dat1 -rrb- on the expression of drug3 and personality trait in woman with drug4 . 
we observe two epistatic interaction on symptom index : interaction -lrb- in predict direction -rrb- of drug1 be see on drug3 -lrb- p = .023 -rrb- , and of drug2 on drug4 -lrb- p = .014 -rrb- , 
study purpose : , analysis of influence of allelic polymorphism c1444t of crp gene drug1 , g -lrb- -174 -rrb- a of il6 gene drug2 , a -lrb- -308 -rrb- g of tnf gene drug3 , g252a of lta gene drug4 , -lrb- -509 -rrb- of tgfb1 gene drug5 and delta32 -lrb- w/d -rrb- of ccr5 gene drug6 on development of drug7 in russian patient with mi during two year follow-up 
method : a total of 51 drug12 patient and 96 unrelated control from West region of Algeria be genotype by direct sequencing for 11 snp include 2 snp from the il10 promoter -lsb- c.-819t > c drug1 , c.-592a > c drug2 , 6 snp from the tnf-a promoter -lsb- c.-1211t > c drug3 , c.-1043c drug4 , c.-1037c > t drug5 , c.-556g > a drug6 , c.-488g > a drug7 , and c.-418g > a drug8 -rsb- , and 3 snp from the il23r-il12rb2 region -lsb- g. 67747415a > c drug9 , g. 67740092g > a drug10 , and g. 67760140t > c drug11 -rsb- . 
result : various snp reach nominal SIGNIFICANCE : drug12 and drug13 with drug1 and drug2 , drug14 with drug3 , drug15 with drug4 , drug16 with drug5 and drug6 , drug17 with drug7 , drug18 with drug8 , drug19 with drug9 , drug10 and drug11 . 
we find a significant genotype effect -lrb- all p < 0.017 -rrb- for the follow smoking-related phenotype : -lrb- i -rrb- cigarette smoke per day and cyp2a13 * 3 ; -lrb- ii -rrb- pack year smoke and cyp2a6 * 2 , cyp2a6 * 1 * 2 , drug1 , cyp2b6 * 4 and drd2-ankk1 2137g > a -lrb- taq1a -rrb- ; -lrb- iii -rrb- drug3 -lrb- assess with the Fagestrom test -rrb- and drug2 . 
the best-studied functional genetic variant relevant to drug2 treatment be drug1 , a single-nucleotide polymorphism in exon 1 of the oprm1 gene that encode the u-opioid receptor . 
method : the association between the oprm1 a118g -lrb- asn40asp , drug1 -rrb- polymorphism and drug2 and alcohol consumption be analyze use three different population-based sample : -lrb- a -rrb- a finnish cohort study , Health 2000 , with 503 participant have a dsm-iv diagnosis for drug3 and/or drug4 and 506 age - and sex-matched control ; -lrb- b -rrb- a finnish cohort study , finrisk -lrb- n = 2360 -rrb- and -lrb- c -rrb- the Helsinki Birth Cohort Study -lrb- n = 1384 -rrb- . 
in the case-control study that include 187patient with drug2 -lrb- case -rrb- and 189 normal subject -lrb- control -rrb- , the AA genotype and variant Met allele frequency of drug1 in the comtgene be significantly higher in patient with drug3 than those in the control group -lrb- both p < 0.05 -rrb- . 
compare with nonsmoker , European-American COMT drug1 double-variant carrier who smoke have increase odds of drug2 -lsb- adjust odds ratio -lrb- aor -rrb- 6.15 , 95 % confidence interval -lrb- ci -rrb- 1.32-28 .78 -rrb- -rsb- ; 
European-American COMT drug1 double-variant carrier who smoke heavily have more frequent moderate or severe drug2 than nonsmoker -lrb- aor 13.7 , 95 % ci 1.2-154 .9 -rrb- . 
European-American drug1 double-variant carrier who smoke describe more frequent moderate or severe drug2 than nonsmoking -lrb- aor 20.6 , 95 % ci 1.64-257 .93 -rrb- and never-smoking -lrb- aor 20.59 , 95 % ci 1.39-304 .68 -rrb- carrier , respectively . 
african-american single-variant drug1 carrier who smoke be more likely to report drug2 than the nonsmoking carrier -lrb- aor 6.16 , 95 % ci 1.11-33 .91 -rrb- . 
this study aim to test the association between the val158met polymorphism drug1 of the catechol-o-methyl transferase gene andanorexia nervosa drug2 . 
the present association study find no association between drug2 and drug1 when test the allelic contrast -lsb- Utrecht odds ratio -lrb- or -rrb- = 1.14 , p = 0.14 ; Leiden or = 1.02 , p = 0.85 -rsb- . 
meta-analytically combine evidence from the present genotyping and the literature search show that the effect size be homogeneous across study and that drug1 be not associate with drug2 . 
the COMT drug1 snp that reduce enzyme activity , have previously be link to drug2 . 
although the drug1 snp be not a risk factor for drug2 , 
we conclude that the functional COMT drug1 snp contribute to drug2 , drug3 and drug4 . 
the author examine relation between reproductive factor and 5 estrogen pathway gene polymorphism -lrb- drug1 , drug2 , drug3 , drug4 , and COMT drug5 -rrb- among 702 Singapore Chinese female drug6 case and 1,578 hospital control , of whom 433 case -lrb- 61.7 % -rrb- and 1,375 control -lrb- 87.1 % -rrb- be never smoker . 
the COMT drug1 a allele be positively associate with drug2 in never smoker -lrb- for g/a or a/a vs. g/g , or = 1.46 , 95 % ci : 1.12 , 1.90 -rrb- but not in ever smoker . 
thus , we hypothesize that -lrb- 1 -rrb- the COMT gene contribute to drug2 and -lrb- 2 -rrb- a COMT polymorphism -lrb- drug1 : val158met -rrb- cause thermolability of enzymatic activity affect liver enzyme -lrb- e.g. , aspartate aminotransferase -lrb- AST -rrb- , alanine aminotransferase -lrb- alt -rrb- and gamma-glutamyl transpeptidase -lrb- Î³-gt -rrb- -rrb- in serum . 
recently we identify two snp in COMT -lrb- drug1 and drug2 -rrb- that be associate with drug3 in a australian cohort . 
individual with drug3 be more than twice as likely to carry the gg genotype compare to the aa genotype for both the drug1 and drug2 snp . 
Association of both drug1 and drug2 withsubstance dependence , a common comorbidity of drug3 have not be investigate . 
the drug1 snp be associate with drug2 . 
the drug1 snp show a weak association with drug2 at the allele level that do not reach significance at the genotype level but it be not associate with drug3 . 
analysis of drug1 haplotype also reveal association with drug2 with the g/ghaplotype be almost 1.5 time more common in drug3 case . 
it be possible that the drug1 snp , in combination with drug2 , result in a common molecular variant of COMT that contribute to drug3 and drug4 susceptibility . 
however , when this relation be assess within strata base on estrogen-related factor , a few snp -lrb- hsd17b1 -lrb- drug1 , drug2 and drug3 -rrb- , comt -lrb- drug4 -rrb- , ugt1a1 -lrb- drug5 -rrb- and esr1 -lrb- drug6 -rrb- seem to be relate to drug7 in the same direction of they association with drug8 . 
we examine variation in maternal and fetal comt gene and they association with drug5 -lrb- term vs preterm pregnancy -rrb- use 4 functional snp : drug1 , drug2 , drug3 , and drug4 in both aa and cau . 
in conclusion , we study demonstrate that a synonymous polymorphism , drug1 in the fetal comt gene , be associate with drug2 in aa . 
variant of drug1 drug2 and drug3 be not associate with the risk of develop drug4 . 
a common c-g-c-c-g-a haplotype for drug1 - drug2 - drug3 - drug4 - drug5 - drug6 show a inverse association with drug7 risk in hispanic caucasian -lrb- or = 0.19 , p = 0.04 , 95 % ci = 0.04-0 .95 -rrb- and with aggressive disease status -lrb- i.e. gleason score > or = 7 -rrb- in non-hispanic caucasian case -lrb- or = 0.64 , p = 0.008 , 95 % ci = 0.47-0 .89 -rrb- . 
a subset of 82 patient also undergo drug8 testing , patient be genotype for the mthfr 677c > t drug1 drug2 , mtr 2756a > g drug3 mtrr 203a > g drug4 , folh1 484t > c drug5 , RFC 80a > g drug6 and comt675g > a drug7 polymorphism . 
a common val - > Met polymorphism -lrb- drug1 -rrb- in the COMT gene , associate with increase prefrontal dopamine catabolism , impair prefrontal cognition and might increase risk for drug2 . 
we have previously find a association with drug1 and drug2 addiction . 
we result suggest that individual susceptibility to drug4 incidence may be increase by combined effect of the high-risk genotype in drug1 , drug2 , and drug3 estrogen metabolic gene . 
the val108/158met drug1 single nucleotide polymorphism -lrb- snp -rrb- in the catechol-o-methyltransferase -lrb- comt -rrb- gene contribute to genetic susceptibility to drug2 , which be specifically related to impairment in executive functioning . 
a different genomic region compose of three snp -lrb- drug1 , drug2 , drug3 -rrb- within the COMT gene have be report to be significantly associate with drug4 in Ashkenazi Jews . 
the snp drug1 , which have be map to the 3 ' - utr region of the COMT gene , be significantly associate with drug2 in we family study , and possibly associate with the age of onset , delusion/hallucination symptom dimension , and CPT performance . 
therefore , COMT may contribute to the genetic risk for drug2 not through the drug1 polymorphism , but through other variant that be situate 3 ' to this region , in the taiwanese population . 
objective : the t allele of a functional polymorphism -lrb- drug1 : lct-13910 c > t -rrb- , close to the lactase gene , correlate with drug2 -lrb- lp -rrb- in adult . 
we aim be to test in this study , the association of drug1 with bmi and related drug2 , in interaction with dairy product consumption . 
drug2 -lrb- pli -rrb- be define as the C/C genotype of the drug1 polymorphism . 
we hypothesize that individual with the drug2 allele of the LCT snp -lrb- drug1 -rrb- would exhibit a greater degree of drug3 and that this relationship would be mediate by lactose consumption . 
the c/t -13910 lactasevariant -lrb- drug1 -rrb- be genotype in 630 man with drug2 and 873 match control participant . 
the -13910 c > t polymorphism -lrb- drug1 -rrb- upstream from the lactase -lrb- lct -rrb- gene , strongly associate with drug2 -lrb- lp -rrb- in Europeans , be emerge as a new candidate for drug3 . 
in contrast , haplotype at another block tag by drug1 associate with prevalent drug2 -lrb- b = 0.239 , p = 2.05 * 10 -lrb- -4 -rrb- -rrb- , but remarkably these be inversely associate with disease severity -lrb- b = -0.196 , p = 0.003 -rrb- . 
the presence of four common oxytocin receptor gene polymorphism -lrb- drug1 , drug2 , drug3 and drug4 -rrb- be evaluate in one hundred woman with drug5 and one hundred healthy woman use restriction fragment length polymorphism genotyping . 
in haplotype analysis , the haplotype combination of drug1 a allele , drug2 c allele and drug3 g allele be find to be significantly associate with a increase risk of drug4 -lrb- or = 3.2 -lsb- ci 1.04-9 .8 -rsb- , p = 0.043 -rrb- . 
with respect to oxtr drug1 , mother with the gg genotype show greater drug2 across vary level of interparental conflict . 
the aim of this study be to investigate whether a set of single nucleotide polymorphism -lrb- snp -rrb- within cyclooxygenase-2 -lrb- cox-2 , drug1 and drug2 -rrb- and oxytocin receptor -lrb- oxtr , drug3 and drug4 -rrb- gene be associate with drug5 , response or remission . 
for this purpose , two single nucleotide polymorphism -lrb- snp -rrb- , 6930g > a -lrb- drug1 -rrb- and 9073g > a -lrb- drug2 -rrb- , within the oxytocin receptor gene -lrb- oxtr -rrb- , be study in a cohort of 185 patient with major drug3 -lrb- 50.3 % -rrb- or drug4 i or ii disorder -lrb- 49.7 % -rrb- and 192 match healthy control . 
a positive association between the gg genotype of drug1 snp -lrb- 6930g > a or 9073g > a -rrb- and unipolar drug2 be demonstrate . 
for drug1 , overtransmission of the g allele to proband with drug2 disorder be find which contrast with the overtransmission of a previously report in the chinese han sample . 
result : the family-based association test -lrb- fbat -rrb- reveal a significant genetic association between drug3 and two of the snp test -lrb- drug1 a : z = 2.287 , p = .0222 ; drug2 a : z = 2.573 , p = .0101 -rrb- . 
when haplotype be construct with two , three , and four marker , the haplotype-specific fbat reveal that a number of haplotype , particularly those involve drug1 , be significantly associate with drug2 . 
conclusion : we meta-analysis suggest that the g allele of drug1 polymorphism might be a potential risk factor for drug2 , especially in whitepopulation . 
the real-time polymerase chain reaction -lrb- rt-pcr -rrb- be use to analyze 4 snp -lrb- drug1 a/g , drug2 a/g , drug3 a/g , drug4 c/g -rrb- in 291 drug5 patient and 247 control . 
analysis of 4 snp reveal a significant difference in the genotype distribution for drug1 , drug2 , and drug3 between drug5 patient and control -lrb- p = 0.041 , p = 0.005 , p = 0.023 , respectively -rrb- but not for drug4 -lrb- p = 0.211 -rrb- . 
minor allele in three correlate ht snp -lrb- drug1 , , drug2 , and drug3 ; r -lrb- 2 -rrb- > 0.6 -rrb- be associate with increase risk for drug4 . 
